Primary cutaneous peripheral T-cell lymphoma not otherwise specified

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

4 events
Feb 2026SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma

The First Affiliated Hospital with Nanjing Medical University — PHASE2

TrialNOT YET RECRUITING
Apr 2023A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

The First Affiliated Hospital with Nanjing Medical University

TrialRECRUITING
Jul 2014

Beleodaq: FDA approved

Treatment of patients with relapsed or refractory peripheral T-cell lymphoma

FDAcompleted
Aug 2011

Adcetris: FDA approved

The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

4 programs

FINANCIAL LANDSCAPE SUMMARY

4

Total programs

4

Open now

Patient Assistance Programs4

POLIVY

Genentech, Inc.

OpenContact for detailsApply ↗

Beleodaq

Acrotech Biopharma LLC

OpenContact for detailsApply ↗

Folotyn

Acrotech Biopharma LLC

OpenContact for detailsApply ↗

Ontak

Eisai, Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

5 FDA-approved

Beleodaq

(Belinostat)Orphan drug

Acrotech Biopharma LLC

Histone Deacetylase Inhibitor [EPC]

12.1 Mechanism of Action Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from the lysine residues of h...

Approved Jul 2014FDA label ↗

POLIVY

(POLATUZUMAB VEDOTIN)standard

Genentech, Inc.

12.1 Mechanism of Action Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. The small molecu...

FDA label ↗

Folotyn

(pralatrexate)Orphan drugaccelerated

Acrotech Biopharma LLC

Folate Analog Metabolic Inhibitor [EPC]

12.1 Mechanism of Action Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competi...

FDA label ↗

Ontak

(denileukin diftitox)Orphan drugstandard

Eisai, Inc.

CD25-directed Cytotoxin [EPC]

12.1 Mechanism of Action Denileukin diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (DT) to cells which ...

FDA label ↗

Lymphir

(denileukin diftitox-cxdl)Orphan drugstandard

Citius Oncology, Inc.

CD25-directed Cytotoxin [EPC]

12.1 Mechanism of Action Denileukin diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (DT) to cells which ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1Unknown
1Total recruiting
Search clinical trials for Primary cutaneous peripheral T-cell lymphoma not otherwise specified

Recent News & Research

1 article
BREAKINGFDA

FDA Approves POLIVY

POLIVY (POLATUZUMAB VEDOTIN-PIIQ) received FDA approval.

Read ↗

Browse all Primary cutaneous peripheral T-cell lymphoma not otherwise specified news →

Specialist Network

Top 6 by expertise

View all Primary cutaneous peripheral T-cell lymphoma not otherwise specified specialists →

Quick Actions